This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in future innovations in oncology, including: ImmunoGen announcing that their Phase II FORWARD I trial failed to meet its primary endpoint of progression-free survival (PFS); Novocure announcing initiation of their pivotal Phase III INNOVATE-3 trial to test the efficacy of tumour treating fields (TTFs) combined with paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC); and Seattle Genetics/Genmab A/S announcing the completion of enrolment in the potentially pivotal InnovaTV 204 Phase II study for tisotumab vedotin.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved